摘要
近期国内流行以呼吸系统症状为主要临床表现的新型冠状病毒肺炎,这是由严重急性呼吸综合征冠状病毒Ⅱ型(SARS-CoV-2)感染引起的。炎症性肠病(IBD)主要是由肠黏膜免疫功能紊乱引起以腹痛、腹泻、营养不良等表现的疾病。IBD患者接受糖皮质激素、免疫抑制剂和生物制剂等药物治疗,导致机体免疫功能下降。因此,应高度重视预防和治疗IBD患者SARS-CoV-2感染。
Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)causes an infectious pneumonia with the respiratory symptoms as the main clinical manifestation,namely COVID-19.Inflammatory bowel disease(IBD)is mainly caused by intestinal mucosal immune dysregulation with symptoms of abdominal pain,diarrhea,and malnutrition.Patients with IBD receive treatments with glucocorticoids,immunosuppresants and biologics,which may lead to immunocompromission.Therefore,the prevention and clinical treatment against SARS-CoV-2 infection in these patients should be highly warranted.
出处
《中华炎性肠病杂志（中英文）》
2020年第2期81-83,共3页
Chinese Journal of Inflammatory Bowel Diseases
